# Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)

> **NCT00338780** · PHASE4 · COMPLETED · sponsor: **Chinese University of Hong Kong**

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Lamivudine/ Placebo 100mg daily

## Key facts

- **NCT ID:** NCT00338780
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** —
- **Final completion:** 2005-01
- **Target enrollment:** — (—)
- **Last updated:** 2006-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00338780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00338780, "Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00338780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*